Company news

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news

Alnylam Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 29, 2026: AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories…

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news

Press releases & updates

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Alnylam to Host Tenth "RNAi Roundtable" Webcast Series

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Issues 2025 Corporate Responsibility Report

ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alnylam to Webcast TTR Investor Webinar

Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors

Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Adimab Reports Strong Partnering Year for 2025

Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

Annual Changes to the Nasdaq-100 Index®

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals Announces Changes to Board of Directors

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine